

# **Eosinophilia Therapeutics Market Forecasts to 2032 – Global Analysis By Drug Class (Corticosteroids, Monoclonal Antibodies (Biologics), Immunosuppressants, Proton Pump Inhibitors (PPIs) and Other Drug Classes), Disease Type, Route of Administration, Distribution Channel, End User and By Geography**

<https://marketpublishers.com/r/E0D15826B6DEEN.html>

Date: July 2025

Pages: 150

Price: US\$ 4,150.00 (Single User License)

ID: E0D15826B6DEEN

## **Abstracts**

According to Statistics MRC, the Global Eosinophilia Therapeutics Market is accounted for \$454.3 million in 2025 and is expected to reach \$724.7 million by 2032 growing at a CAGR of 6.9% during the forecast period. Eosinophilia therapeutics encompass a range of treatments designed to manage elevated eosinophil levels, which can result from allergic conditions, parasitic infections, or specific disorders like hypereosinophilic syndrome (HES) and eosinophilic asthma. Therapies include corticosteroids, immunosuppressants, and targeted biologics such as anti-IL-5, anti-IL-4R?, and anti-IgE monoclonal antibodies. These therapeutics aim to reduce eosinophilic inflammation, prevent organ damage, and improve patient outcomes by modulating the underlying immune response.

According to the European Medicines Agency (EMA), the estimated prevalence of hypereosinophilic syndrome (HES) is 1.5 per 100,000 people.

Market Dynamics:

Driver:

Increasing prevalence of eosinophilic disorders

The rising incidence of eosinophilic disorders serves as a primary growth driver. This increase stems from enhanced diagnostic capabilities that enable earlier detection of rare eosinophilia-related conditions, coupled with growing environmental factors contributing to allergic and inflammatory diseases. Heightened clinical awareness among healthcare professionals has led to improved recognition of eosinophilic asthma, hypereosinophilic syndrome, and eosinophilic esophagitis. The expanding patient population creates substantial demand for targeted treatments, driving pharmaceutical companies to invest heavily in research and development of specialized therapies to address these complex immunological conditions.

#### Restraint:

##### High cost of novel therapies

Monoclonal antibodies and targeted biologics, while highly effective, command premium pricing that limits patient accessibility and healthcare system adoption. The specialized nature of these therapies requires extensive clinical trials and regulatory approval processes, contributing to elevated development costs that are ultimately passed to consumers. Insurance coverage limitations and reimbursement challenges further restrict market penetration, particularly in emerging economies where healthcare budgets are constrained, creating disparities in treatment access across different patient populations.

#### Opportunity:

##### Development of next-generation biologics and precision medicine

The advancement of precision medicine approaches and innovative biologics targeting specific pathways like IL-5, IL-4, and IL-13 represents tremendous market potential. Ongoing clinical trials of novel eosinophil-targeting therapeutic agents are expanding treatment options beyond traditional corticosteroids. Moreover, personalized medicine strategies enable tailored treatment protocols based on individual patient profiles, improving therapeutic outcomes while reducing adverse effects. The growing understanding of eosinophilic disease mechanisms facilitates the development of more targeted interventions, creating opportunities for pharmaceutical companies to capture market share through differentiated products that address unmet medical needs.

#### Threat:

## Emergence of biosimilars

As patents for original monoclonal antibodies expire, biosimilar manufacturers can offer cost-effective alternatives that potentially erode the market share of branded products. Furthermore, regulatory agencies are streamlining approval pathways for biosimilars, accelerating their market entry and increasing competitive pressure on innovator companies. This threat intensifies price competition and may compress profit margins, forcing original manufacturers to demonstrate superior clinical value or develop next-generation therapies in an increasingly commoditized therapeutic environment.

## Covid-19 Impact:

The COVID-19 pandemic significantly impacted the eosinophilia therapeutics market through delayed diagnoses and postponed routine medical consultations. Healthcare systems prioritized pandemic response, leading to reduced screening for eosinophilic disorders and interrupted treatment continuity. However, the crisis accelerated telemedicine adoption and digital health integration, creating new patient engagement channels. Additionally, heightened focus on respiratory conditions during the pandemic increased awareness of eosinophilic asthma, potentially driving future market growth as healthcare services normalize.

The corticosteroids segment is expected to be the largest during the forecast period

The corticosteroids segment is expected to account for the largest market share during the forecast period due to their proven effectiveness in rapidly controlling inflammation and their established role as first-line therapy for various eosinophilic conditions. These medications offer broad applicability across allergic, autoimmune, and idiopathic eosinophilic disorders while providing fast symptom relief and accessibility in outpatient settings. Their cost-effectiveness compared to newer biologics makes them preferred choices among clinicians, particularly in resource-constrained healthcare environments, ensuring their sustained market leadership.

The online pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the online pharmacies segment is predicted to witness the highest growth rate, driven by increasing digital healthcare adoption and patient preference for convenient medication access. Digital platforms offer enhanced patient

education resources, medication adherence support, and streamlined prescription management systems that improve treatment outcomes. Moreover, the COVID-19 pandemic accelerated e-commerce adoption in healthcare, establishing online pharmacies as viable alternatives to traditional retail channels. Additionally, these platforms often provide competitive pricing, home delivery services, and specialized support for chronic conditions, making them particularly attractive for eosinophilia patients requiring long-term therapeutic management and regular medication refills.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its advanced healthcare infrastructure and high adoption rates of evidence-based pharmacological therapies for eosinophilic disorders. The region benefits from the strong presence of key biopharmaceutical companies specializing in immunological treatments, robust regulatory frameworks, and comprehensive insurance coverage supporting biologic therapies. Furthermore, heightened clinical awareness among healthcare professionals and superior diagnostic capabilities enable early detection and effective management of eosinophil-associated diseases in the region.

Region with highest CAGR:

During the forecast period, the North America region is expected to hold the largest market share due to expanding healthcare infrastructure and increasing awareness of allergic and immunological disorders across the region. Countries like China, India, and Japan represent high-potential markets due to the growing prevalence of eosinophilic diseases, improved diagnostic capabilities, and rising healthcare expenditure. Additionally, enhanced access to biologics and corticosteroid alternatives, combined with growing physician education on eosinophilic disorders, drives strong market expansion. Moreover, government healthcare policies create favorable conditions, positioning Asia Pacific as the fastest growing region.

Key players in the market

Some of the key players in Eosinophilia Therapeutics Market include Allakos, Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Cipla Inc., Eli Lilly & Company, Gilead Sciences, Inc., GlaxoSmithKline plc (GSK), Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Takeda Pharmaceutical Company Ltd., Arena Pharmaceuticals Ltd., Ellodi Pharmaceuticals, and Revolo Biotherapeutics.

## Key Developments:

In May 2025, GSK plc announced that the US Food and Drug Administration (FDA) have approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype. FDA's approval was based on data from the positive MATINEE and METREX phase III trials. Across these trials, mepolizumab showed a clinically meaningful and statistically significant reduction in the annualised rate of moderate/severe exacerbations versus placebo in a wide spectrum of COPD patients with an eosinophilic phenotype.

In May 2025, AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Francisco, CA from 16 to 21 May 2025. With more than 75 abstracts, including eight late-breakers, the Company continues to drive innovation and address unmet needs in care across all severities of asthma, chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis (EGPA) and other chronic inflammatory diseases.

In February 2024, Takeda announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE).<sup>1</sup> It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.

## Drug Classes Covered:

Corticosteroids

Monoclonal Antibodies (Biologics)

Immunosuppressants

Proton Pump Inhibitors (PPIs)

Other Drug Classes

## Disease Types:

Hypereosinophilic Syndrome (HES)

Eosinophilic Esophagitis (EoE)

Eosinophilic Asthma

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Other Eosinophilic Disorders

Route of Administrations:

Oral

Parenteral (Injectable)

Inhalation

Topical

Distribution Channels Covered:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Direct Distribution

End Users Covered:

Hospitals

Specialty Clinics

Homecare Settings

Other Healthcare Facilities

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments

- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

#### Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

#### Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

#### Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

## Contents

### **1 EXECUTIVE SUMMARY**

### **2 PREFACE**

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
  - 2.4.1 Data Mining
  - 2.4.2 Data Analysis
  - 2.4.3 Data Validation
  - 2.4.4 Research Approach
- 2.5 Research Sources
  - 2.5.1 Primary Research Sources
  - 2.5.2 Secondary Research Sources
  - 2.5.3 Assumptions

### **3 MARKET TREND ANALYSIS**

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19

### **4 PORTERS FIVE FORCE ANALYSIS**

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

### **5 GLOBAL EOSINOPHILIA THERAPEUTICS MARKET, BY DRUG CLASS**

- 5.1 Introduction
- 5.2 Corticosteroids
- 5.3 Monoclonal Antibodies (Biologics)
  - 5.3.1 Anti-IL-5/IL-5R?
  - 5.3.2 Anti-IL-4R?
  - 5.3.3 Anti-IgE
  - 5.3.4 Other Emerging Biologics
- 5.4 Immunosuppressants
  - 5.4.1 Hydroxyurea
  - 5.4.2 Interferon-?
  - 5.4.3 Imatinib
- 5.5 Proton Pump Inhibitors (PPIs)
- 5.6 Other Drug Classes

## **6 GLOBAL EOSINOPHILIA THERAPEUTICS MARKET, BY DISEASE TYPE**

- 6.1 Introduction
- 6.2 Hypereosinophilic Syndrome (HES)
- 6.3 Eosinophilic Esophagitis (EoE)
- 6.4 Eosinophilic Asthma
- 6.5 Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- 6.6 Other Eosinophilic Disorders

## **7 GLOBAL EOSINOPHILIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION**

- 7.1 Introduction
- 7.2 Oral
- 7.3 Parenteral (Injectable)
- 7.4 Inhalation
- 7.5 Topical

## **8 GLOBAL EOSINOPHILIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL**

- 8.1 Introduction
- 8.2 Hospital Pharmacies
- 8.3 Retail Pharmacies

8.4 Online Pharmacies

8.5 Direct Distribution

## **9 GLOBAL EOSINOPHILIA THERAPEUTICS MARKET, BY END USER**

9.1 Introduction

9.2 Hospitals

9.3 Specialty Clinics

9.4 Homecare Settings

9.5 Other Healthcare Facilities

## **10 GLOBAL EOSINOPHILIA THERAPEUTICS MARKET, BY GEOGRAPHY**

10.1 Introduction

10.2 North America

10.2.1 US

10.2.2 Canada

10.2.3 Mexico

10.3 Europe

10.3.1 Germany

10.3.2 UK

10.3.3 Italy

10.3.4 France

10.3.5 Spain

10.3.6 Rest of Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 New Zealand

10.4.6 South Korea

10.4.7 Rest of Asia Pacific

10.5 South America

10.5.1 Argentina

10.5.2 Brazil

10.5.3 Chile

10.5.4 Rest of South America

10.6 Middle East & Africa

- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa

## **11 KEY DEVELOPMENTS**

- 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 11.2 Acquisitions & Mergers
- 11.3 New Product Launch
- 11.4 Expansions
- 11.5 Other Key Strategies

## **12 COMPANY PROFILING**

- 12.1 Allakos, Inc.
- 12.2 AstraZeneca plc
- 12.3 Bayer AG
- 12.4 Bristol-Myers Squibb
- 12.5 Cipla Inc.
- 12.6 Eli Lilly & Company
- 12.7 Gilead Sciences, Inc.
- 12.8 GlaxoSmithKline plc (GSK)
- 12.9 Hoffmann-La Roche Ltd.
- 12.10 Merck & Co., Inc.
- 12.11 Novartis AG
- 12.12 Pfizer Inc.
- 12.13 Regeneron Pharmaceuticals, Inc.
- 12.14 Sanofi S.A.
- 12.15 Takeda Pharmaceutical Company Ltd.
- 12.16 Arena Pharmaceuticals Ltd.
- 12.17 Ellodi Pharmaceuticals
- 12.18 Revolo Biotherapeutics

## List Of Tables

### LIST OF TABLES

Table 1 Global Eosinophilia Therapeutics Market Outlook, By Region (2024-2032) (\$MN)

Table 2 Global Eosinophilia Therapeutics Market Outlook, By Drug Class (2024-2032) (\$MN)

Table 3 Global Eosinophilia Therapeutics Market Outlook, By Corticosteroids (2024-2032) (\$MN)

Table 4 Global Eosinophilia Therapeutics Market Outlook, By Monoclonal Antibodies (Biologics) (2024-2032) (\$MN)

Table 5 Global Eosinophilia Therapeutics Market Outlook, By Anti-IL-5/IL-5R? (2024-2032) (\$MN)

Table 6 Global Eosinophilia Therapeutics Market Outlook, By Anti-IL-4R? (2024-2032) (\$MN)

Table 7 Global Eosinophilia Therapeutics Market Outlook, By Anti-IgE (2024-2032) (\$MN)

Table 8 Global Eosinophilia Therapeutics Market Outlook, By Other Emerging Biologics (2024-2032) (\$MN)

Table 9 Global Eosinophilia Therapeutics Market Outlook, By Immunosuppressants (2024-2032) (\$MN)

Table 10 Global Eosinophilia Therapeutics Market Outlook, By Hydroxyurea (2024-2032) (\$MN)

Table 11 Global Eosinophilia Therapeutics Market Outlook, By Interferon-? (2024-2032) (\$MN)

Table 12 Global Eosinophilia Therapeutics Market Outlook, By Imatinib (2024-2032) (\$MN)

Table 13 Global Eosinophilia Therapeutics Market Outlook, By Proton Pump Inhibitors (PPIs) (2024-2032) (\$MN)

Table 14 Global Eosinophilia Therapeutics Market Outlook, By Other Drug Classes (2024-2032) (\$MN)

Table 15 Global Eosinophilia Therapeutics Market Outlook, By Disease Type (2024-2032) (\$MN)

Table 16 Global Eosinophilia Therapeutics Market Outlook, By Hypereosinophilic Syndrome (HES) (2024-2032) (\$MN)

Table 17 Global Eosinophilia Therapeutics Market Outlook, By Eosinophilic Esophagitis (EoE) (2024-2032) (\$MN)

Table 18 Global Eosinophilia Therapeutics Market Outlook, By Eosinophilic Asthma

(2024-2032) (\$MN)

Table 19 Global Eosinophilia Therapeutics Market Outlook, By Eosinophilic Granulomatosis with Polyangiitis (EGPA) (2024-2032) (\$MN)

Table 20 Global Eosinophilia Therapeutics Market Outlook, By Other Eosinophilic Disorders (2024-2032) (\$MN)

Table 21 Global Eosinophilia Therapeutics Market Outlook, By Route of Administration (2024-2032) (\$MN)

Table 22 Global Eosinophilia Therapeutics Market Outlook, By Oral (2024-2032) (\$MN)

Table 23 Global Eosinophilia Therapeutics Market Outlook, By Parenteral (Injectable) (2024-2032) (\$MN)

Table 24 Global Eosinophilia Therapeutics Market Outlook, By Inhalation (2024-2032) (\$MN)

Table 25 Global Eosinophilia Therapeutics Market Outlook, By Topical (2024-2032) (\$MN)

Table 26 Global Eosinophilia Therapeutics Market Outlook, By Distribution Channel (2024-2032) (\$MN)

Table 27 Global Eosinophilia Therapeutics Market Outlook, By Hospital Pharmacies (2024-2032) (\$MN)

Table 28 Global Eosinophilia Therapeutics Market Outlook, By Retail Pharmacies (2024-2032) (\$MN)

Table 29 Global Eosinophilia Therapeutics Market Outlook, By Online Pharmacies (2024-2032) (\$MN)

Table 30 Global Eosinophilia Therapeutics Market Outlook, By Direct Distribution (2024-2032) (\$MN)

Table 31 Global Eosinophilia Therapeutics Market Outlook, By End User (2024-2032) (\$MN)

Table 32 Global Eosinophilia Therapeutics Market Outlook, By Hospitals (2024-2032) (\$MN)

Table 33 Global Eosinophilia Therapeutics Market Outlook, By Specialty Clinics (2024-2032) (\$MN)

Table 34 Global Eosinophilia Therapeutics Market Outlook, By Homecare Settings (2024-2032) (\$MN)

Table 35 Global Eosinophilia Therapeutics Market Outlook, By Other Healthcare Facilities (2024-2032) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

## I would like to order

Product name: Eosinophilia Therapeutics Market Forecasts to 2032 – Global Analysis By Drug Class (Corticosteroids, Monoclonal Antibodies (Biologics), Immunosuppressants, Proton Pump Inhibitors (PPIs) and Other Drug Classes), Disease Type, Route of Administration, Distribution Channel, End User and By Geography

Product link: <https://marketpublishers.com/r/E0D15826B6DEEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E0D15826B6DEEN.html>